湯姆貓(300459.SZ):目前公司湯姆貓家族IP系列產品暫未上線蘋果MR頭顯終端
格隆匯7月25日丨有投資者向湯姆貓(300459.SZ)提問,“公司如何迎接蘋果MR生態?”,公司回覆稱,除移動手機終端外,公司現有湯姆貓家族IP遊戲產品已先後拓展了華為智慧屏、華為車載智能終端、RokidAR眼鏡、谷歌車載系統等智能終端應用場景,湯姆貓家族IP系列遊戲產品已具備多終端、多場景延伸的優勢。截至目前,公司湯姆貓家族IP系列產品暫未上線蘋果MR頭顯終端,未來,隨着VR、MR等智能終端的不斷突破與持續發展,公司也將緊跟市場需求,覆蓋更多體驗場景與新型智能終端。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.